Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease

Conclusion The results of our study have shown that patients with < 20% cellularity and < 20% blasts on the D14 bone marrow assessment should continue observation until recovery rather than receive additional immediate therapy. Micro-Abstract In our single center retrospective study of day 14 bone marrow assessment in AML, we found cellularity to be a stronger predictor of response than blast percentage or receipt of re-induction chemotherapy. For patients with blast percent and cellularity.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research